Agenus vs Monte Rosa Therapeutics
AGEN and GLUE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AGEN and GLUE compare
Monte Rosa Therapeutics is the larger company, worth 2.7 times as much as Agenus ($774M against $283M).
Agenus grew revenue faster over the last twelve months (30.5% versus −83.9% for Monte Rosa Therapeutics).
Monte Rosa Therapeutics scores higher on the StockData Score (7 against 3 for Agenus), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AGEN | GLUE |
|---|---|---|
| Size and price | ||
| Market cap | $283M | $774M |
| Share price | $6.29 | $9.07 |
| Change, 1 year | 45.3% | −36.8% |
| Change, 5 years | −90.3% | −55.9% |
| Beta (5Y) | 1.01 | 2.02 |
| Employees | 81 | 150 |
| StockData Score | ||
| Total score | 3 | 7 (better) |
| Valuation score | 1 | 1 |
| Growth score | 2 (better) | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 0 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 2.1× (better) | 26.9× |
| P/B | – | 1.6× |
| EV/EBITDA | 7.0× | – |
| FCF yield | −34.8% | −4.1% (better) |
| Fair value | – | $6.54 |
| Margin of safety | – | −38.7% |
| Growth | ||
| Revenue growth (TTM) | 30.5% (better) | −83.9% |
| Revenue growth, 5Y average | 5.3% | – |
| Net income growth (TTM) | – | −767% |
| EPS growth (TTM) | – | −707% |
| Profitability | ||
| Gross margin | 99.5% | – |
| Operating margin | 27.3% (better) | −633% |
| Net margin | – | −561% |
| FCF margin | −74.2% (better) | −112% |
| Return on equity | – | −42.7% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Net debt / EBITDA | 0.28 | – |
| Interest coverage | 0.6× | – |
| Current ratio | 0.34 | 10.58 (better) |
| Altman Z-score | −16.54 | 1.30 (better) |
| Piotroski F-score | – | 5 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 31.7% | 109% |
| Held by insiders | 6.6% | 11.5% |
| Insider net buying, 12 months | – | −$4.1M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 18.1% | 27.6% |
Go deeper
- AGEN stock overview
- AGEN income statement
- AGEN valuation and score
- GLUE stock overview
- GLUE income statement
- GLUE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.